(Q44111170)

English

Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers

scientific article published in April 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

John M. Watkins

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Keisuke S Shirai

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Amy E Wahlquist

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Uzair B Chaudhary

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Elizabeth Garrett-Mayer

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Terry A Day

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

M Boyd Gillespie

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Anand K Sharma

9

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

493-502

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

21 January 2018

Salvage re-irradiation for recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

21 January 2018

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

21 January 2018

Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

21 January 2018

Head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage surgery after failed primary concomitant chemoradiation

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose reirradiation of head and neck cancer with curative intent

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1002%2FHED.20986

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HED.20986

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44111170&oldid=2106693544"